/

Società

Aj

Non verificato

Ajax Therapeutics, Inc.

Di cosa scriviamo

FarmaceuticaIndustriaMedicina - VarieSaluteVetrine/Shopping

2 comunicati stampa

Guarda tutti i comunicati

02/12/2024

Industria

Biotecnologia

Farmaceutica

Salute

Medicina - Varie

Ajax Therapeutics to Present Overview of Phase 1 Clinical Trial Evaluating AJ1‑11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis at the American Society of Hematology Annual Meeting

Fonte

Ajax Therapeutics, Inc.

Emittente

1.00

0

30/10/2024

Industria

Biotecnologia

Salute

Farmaceutica

Medicina - Varie

Oncologia

Ajax Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating AJ1-11095, a First-in-Class Type II JAK2 inhibitor, for the Treatment of Myelofibrosis

Fonte

Ajax Therapeutics, Inc.

Emittente

1.00

0

Seguaci

0

Compatibilità

0